Who Owns Acrivon Therapeutics Stock?
NASDAQ: ACRVHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 50.34%
- Held by insiders
- 15.40%
- Institutional holders
- 56
- Institutions 50.3%
- Insiders 15.4%
- Public and other 34.3%
Who owns Acrivon Therapeutics stock?
Institutional investors own about 50.3% of Acrivon Therapeutics's shares, spread across 56 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 15.40% of ACRV.
The largest institutional holders are RA Capital Management, L.P. (28.54%), Sands Capital Alternatives, LLC (5.34%) and Acadian Asset Management. LLC (2.72%). Together, the top 10 institutions control 46.9% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their ACRV positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ACRV
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 12.23M | 28.54% | +46.6% |
| Sands Capital Alternatives, LLC | 2.29M | 5.34% | +7.8% |
| Acadian Asset Management. LLC | 1.17M | 2.72% | +37.7% |
| Vanguard Capital Management LLC | 952.01K | 2.22% | +31.9% |
| Wellington Management Group, LLP | 888.13K | 2.07% | 0.0% |
| Renaissance Technologies, LLC | 758.86K | 1.77% | +0.1% |
| Two Sigma Investments, LP | 641.50K | 1.50% | +64.7% |
| Marshall Wace LLP | 531.86K | 1.24% | -5.1% |
| Bridgeway Capital Management, LLC | 378.90K | 0.88% | +138.4% |
| Geode Capital Management, LLC | 265.24K | 0.62% | +12.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ACRV
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 545.54K | 1.27% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 389.57K | 0.91% |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 316.00K | 0.74% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 156.59K | 0.37% |
| iShares Trust-iShares Micro-Cap ETF | 73.38K | 0.17% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 42.54K | 0.10% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 24.81K | 0.06% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 21.34K | 0.05% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 16.89K | 0.04% |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 4.94K | 0.01% |
Frequently asked questions
Who is the largest shareholder of Acrivon Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of ACRV, owning 28.54% of shares outstanding (12.23M shares) as of its latest 13F filing.
What percentage of Acrivon Therapeutics is owned by institutions?
Institutions own about 50.3% of ACRV shares and 59.5% of the public float.
How much of Acrivon Therapeutics do insiders own?
Insiders, such as officers and directors, own about 15.40% of ACRV shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.